Dissecting T cell receptor signaling: from Zap70 sensitizing mutations to revealing hidden mutant phenotypes via CRISPR/Cas9

Read full text Summarise with VIRAT
Authors: Vasileios Morfos
Cited by: 0
References: 103

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

T-cell receptor signaling determines the sensitivity, activation threshold and effector functions of T cells, thus small perturbations in this pathway can dramatically reshape immune responses in both health and disease. This doctoral thesis investigates how individual components of the TCR signaling machinery, specifically the Zap70 kinase and the CD3γ and CD3δ subunits, shape antigen recognition and T-cell activation, and introduces a new genetic platform to mechanistically dissect these processes directly in primary murine T cells. In the first project, we examined two Zap70 mutations the R360P and W131A, which were previously proposed to destabilize autoinhibition and favor a more open, signaling-permissive conformation. Based on our hypothesis, by utilizing these Zap70 mutants in T cells, we can lower the TCR activation thresholds enhancing responses to weak tumor neoantigens. We characterized the functional phenotype of these mutants in OT-I TCR knock-in mice. We found that only Zap70 R360P, but not W131A, enhances T-cell sensitivity toward low-affinity antigens. In contrast, W131A T cells were profoundly hyporesponsive upon stimulation. These results identify R360P as a potential molecular sensitizer of TCR signaling and establish a foundation for subsequent in vivo tumor studies to test whether lowering TCR activation thresholds enhances anti-tumor immunity. If validated in vivo, the mechanistic insights from R360P could guide the development of selective allosteric Zap70 activators to therapeutically boost T cell responses against low-affinity tumor antigens. In the second project, we developed a single retroviral CRISPR knockout-re expression vector system optimized for primary murine T cells. This system unifies sgRNA and cDNA expression within a single construct, enabling efficient gene disruption and immediate replacement by wild-type or mutant proteins in the same cell. We first applied this system to CD3γ, demonstrating efficient knockout of the endogenous gene, robust re-expression of CD3γ-GFP, and high incorporation of the tagged replacement protein into functional surface TCR complexes. To further establish the biological versatility of the system, we applied it to the intracellular Zap70 kinase and showed that this approach allows functional characterization of recessive or non-dominant negative mutants in primary T cells unmasking phenotypes that cannot be revealed when endogenous Zap70 is still present. Furthermore, this system supports the generation of genetically modified T cells suitable for downstream in vivo tumor experiments providing a flexible and powerful tool for dissecting TCR signaling in primary T cells. In the third project, we investigated the functional contribution of the ITAM tyrosines in CD3γ and CD3δ subunits. Previous biochemical work from our group showed that Lck preferentially phosphorylates the N-terminal ITAM tyrosines of both subunits in vitro. To examine whether this phosphorylation preference is biologically meaningful in primary T cells, we utilized the CRISPR retroviral transduction system to simultaneously knock out the endogenous CD3γ and CD3δ and re-express the phenylalanine ITAM mutants. Surprisingly, we observed no major differences between the fully mutated and wild-type CD3γ/δ TCR in cytokine production or degranulation, suggesting that the preferential phosphorylation observed biochemically may not translate into distinct functional outcomes in cellular context, or that additional compensatory mechanisms stabilize early TCR signaling. Collectively, this work advances our mechanistic understanding of TCR signaling and provides a foundation for developing new strategies for next-generation novel immunotherapies.

Fields of Study & Subjects

T-cell and B-cell Immunology CAR-T cell therapy research Immunotherapy and Immune Responses

Publication details

Journal / source
FreiDok plus (Universitätsbibliothek Freiburg)
Publication date
30 March 2026
Language
EN
Document type
Thesis